- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Distillery Therapeutics
Inhibiting GLIS2 for autosomal dominant polycystic kidney disease
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | May 10, 2019
Translation in Brief
Tapping mutations for liver regeneration
How liver mutations point the way to new strategies for hepatic regeneration
BioCentury | Feb 17, 2017
Targets & Mechanisms
Gilding the Goldfinch
Why Third Rock is betting Goldfinch can bring innovation to kidney disease
Items per page:
1 - 10 of 12